Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$300.4MCash, Jun 2026
57moCash Runway (est.)
+73%Share Count, 1 Year
Follow CCCC by emailGet an email when CCCC pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CCCC, unsubscribe in one click. Privacy
📣 What CCCC Says Is Next
mid-2027 · “Data from all cohorts evaluated in the Phase 1b trial are expected in mid-2027.”
Company press release, Sep 25, 2026 · SEC filing
first half of 2027 · “The trial is expected to initiate in the first half of 2027 with the goal to characterize cemsidomide’s dose and safety with approved standard of care MM therapies.”
Company press release, Aug 11, 2026 · SEC filing
second half of 2026 · “C4T expects to provide an update on the dose escalation progress in the second half of 2026 with data from all cohorts expected in mid-2027.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
CCCC reported $300.4M in cash and short-term investments (as of Jun 30, 2026) and used about $15.9M/quarter in operations, an estimated runway of 56.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:30 · Moderate
Cash runway 57 months
ATM program on file since Dec 2025 +15
Shelf registration (S-3, Nov 2025) +10
Company says cash lasts to the end of 2028 -15We believe that these funds will be sufficient to fund our planned operating expenses to the end of 2028.10-Q, Aug 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CCCC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.